Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice

Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868 · see citing works

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · see citing works

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L. A., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,183 · see citing works

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715 · see citing works

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689 · see citing works

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Hofmann, L., Forschner, A., Loquai, C., Goldinger, S. M., Zimmer, L., Ugurel, S., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.025 · Cited by 643 · see citing works

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.024 · Cited by 564 · see citing works

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492 · see citing works

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477 · see citing works

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 463 · see citing works

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

Laubli, H. P., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 320 · see citing works

Anti-CTLA4 Antibody–Induced Lupus Nephritis

Fadel, F., Karoui, K. E., & Knebelmann, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904283 · Cited by 300 · see citing works

PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis

Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288 · see citing works

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

Zimmer, L., Vaübel, J., Mohr, P., Hauschild, A., Utikal, J. S., Simon, J. C., Garbe, C., Herbst, R. A., Enk, A., Kämpgen, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118564 · Cited by 268 · see citing works

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

Wang, J., Okazaki, I., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 267 · see citing works

Clinical activity of ipilimumab for metastatic uveal melanoma

Luke, J. J., Callahan, M. K., Postow, M. A., Romano, E., Ramaiya, N. H., Bluth, M. J., Giobbie‐Hurder, A., Lawrence, D. P., Ibrahim, N., Ott, P. A., et al. (2013) · Cancer · doi:10.1002/cncr.28282 · Cited by 192 · see citing works

Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice

Lucas, J. A., Weinmann‐Menke, J., Rabacal, W., Schöen, F. J., Sharpe, A. H., & Kelley, V. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2513 · Cited by 191 · see citing works

Anti-CTLA-4 antibody-induced Guillain–Barré syndrome in a melanoma patient

Wilgenhof, S., & Neyns, B. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr028 · Cited by 175 · see citing works

Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer

Graziani, G., Tentori, L., & Navarra, P. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.09.002 · Cited by 164 · see citing works

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

Geisler, B. P., Raad, R. A., Esaian, D., Sharon, E., & Schwartz, D. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0048-2 · Cited by 144 · see citing works

Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication

Yun, S., Vincelette, N. D., Mansour, I. S. M., Hariri, D. J., & Motamed, S. (2015) · Case Reports in Oncological Medicine · doi:10.1155/2015/794842 · Cited by 130 · see citing works

Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission

Vogel, W. V., Guislain, A., Kvistborg, P., Schumacher, T. N., Haanen, J. B. A. G., & Blank, C. U. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9693 · Cited by 127 · see citing works

Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma

Chan, M. M. K., Kefford, R. F., Carlino, M. S., Clements, A., & Manolios, N. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000060 · Cited by 119 · see citing works

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab

Hunter, G. R. W., Voll, C., & Robinson, C. A. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100007939 · Cited by 106 · see citing works

Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis

Min, L., & Hodi, F. S. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0146 · Cited by 101 · see citing works

CTLA-4 Ablation and Interleukin-12–Driven Differentiation Synergistically Augment Cardiac Pathogenicity of Cytotoxic T Lymphocytes

Love, V. A., Grabie, N., Duramad, P., Stavrakis, G., Sharpe, A. H., & Lichtman, A. H. (2007) · Circulation Research · doi:10.1161/circresaha.106.147124 · Cited by 93 · see citing works

Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss

Voskens, C., Cavallaro, A., Erdmann, M., Dippel, O., Kaempgen, E., Schuler, G., Schuler‐Thurner, B., & Heinzerling, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4359 · Cited by 49 · see citing works

Re-orienting the immune system

Lipson, E. J. (2013) · OncoImmunology · doi:10.4161/onci.23661 · Cited by 30 · see citing works

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · see citing works

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,434 · see citing works

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314 · see citing works

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992 · see citing works

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608 · see citing works

Immune-related adverse events of checkpoint inhibitors

Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,447 · see citing works

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942 · see citing works

A population-based study of cardiovascular disease mortality risk in US cancer patients

Sturgeon, K. M., Deng, L., Bluethmann, S. M., Zhou, S., Trifiletti, D. M., Jiang, C., Kelly, S. P., & Zaorsky, N. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz766 · Cited by 938 · see citing works

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570 · see citing works

Immune checkpoint inhibitors and cardiovascular toxicity

Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575 · see citing works

Cardiovascular toxicities associated with immune checkpoint inhibitors

Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz026 · Cited by 508 · see citing works

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Thompson, J. A., Schneider, B. J., Brahmer, J. R., Andrews, S., Armand, P. A., Bhatia, S., Budde, L. E., Costa, L. J., Davies, M. J., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 488 · see citing works

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Liu, J., Chen, Z., Li, Y., Zhao, W., Wu, J., & Zhang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731798 · Cited by 421 · see citing works

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

Giaccone, G., Kim, C., Thompson, J., McGuire, C., Kallakury, B., Chahine, J. J., Manning, M. A., Mogg, R., Blumenschein, W. M., Tan, M. T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30062-7 · Cited by 410 · see citing works

Immune checkpoint inhibitors in challenging populations

Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339 · see citing works

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

Hassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T., Grimm, M., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 331 · see citing works

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 301 · see citing works

Cardiotoxicity of immune checkpoint inhibitors

Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247 · see citing works

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Ralli, M., Botticelli, A., Visconti, I. C., Angeletti, D., Fiore, M., Marchetti, P., Lambìase, A., VINCENTIIS, M. D., & Greco, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9235638 · Cited by 247 · see citing works

Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors

Moreira, A., Loquai, C., Pföhler, C., Kähler, K. C., Knauß, S., Heppt, M. V., Gutzmer, R., Dimitriou, F., Meier, F. E., Mitzel-Rink, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.033 · Cited by 239 · see citing works

Cardiovascular Toxicities of Immune Checkpoint Inhibitors

Ball, S., Ghosh, R. K., Wongsaengsak, S., Bandyopadhyay, D., Ghosh, G. C., Aronow, W. S., Fonarow, G. C., Lenihan, D. J., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.079 · Cited by 229 · see citing works

Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets

Luo, X., Wu, K., & He, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01968-w · Cited by 203 · see citing works

Smoldering myocarditis following immune checkpoint blockade

Norwood, T. G., Westbrook, B. C., Johnson, D. B., Litovsky, S. H., Terry, N. L. J., McKee, S. B., Gertler, A. S., Moslehi, J. J., & Conry, R. M. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0296-4 · Cited by 203 · see citing works

Cancer Treatment–Induced Arrhythmias

Buza, V., Rajagopalan, B., & Curtis, A. B. (2017) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.117.005443 · Cited by 194 · see citing works

Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis

Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H., Sultan, D., Bredemeyer, A., Bajapa, G., Feng, G., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.062551 · Cited by 187 · see citing works

The Innate Immune System in Chronic Cardiomyopathy: A European Society of Cardiology (Esc) Scientific Statement from the Working Group on Myocardial Function of the ESC

Frantz, S., Falcão‐Pires, I., Balligand, J., Bauersachs, J. K., Brutsaert, D. L., Ciccarelli, M., Dawson, D. K., Windt, L. J. D., Giacca, M., Hamdani, N., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1138 · Cited by 188 · see citing works

Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study

Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., et al. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3750 · Cited by 179 · see citing works

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis: A Narrative Review

Lehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178 · see citing works

The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study

D’Souza, M., Nielsen, D. L., Svane, I. M., Iversen, K. K., Rasmussen, P. V., Madelaire, C., Fosbøl, E. L., Køber, L., Gustafsson, F., Andersson, C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa884 · Cited by 172 · see citing works

Cardiovascular Toxicities Associated with Cancer Immunotherapies

Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 160 · see citing works

AIEgen-coupled upconversion nanoparticles eradicate solid tumors through dual-mode ROS activation

Mao, D., Hu, F., Yi, Z., Kenry, K., Xu, S., Yan, S., Luo, Z., Wu, W., Wang, Z., Kong, D., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2712 · Cited by 153 · see citing works

Cardiotoxicity of Immune Checkpoint Inhibitors

Patel, R. P., Parikh, R. B., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01070-6 · Cited by 152 · see citing works

Electroimmunology and cardiac arrhythmia

Grune, J., Yamazoe, M., & Nahrendorf, M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00520-9 · Cited by 152 · see citing works

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity

Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. L., & Neilan, T. G. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 145 · see citing works

Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis

written on behalf of the AME Academic Lung Cancer Cooperation Group, Hu, Y., Zhang, Q., Li, H., Michot, J., Liu, H., Zhan, P., Lv, T., & Song, Y. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.12.10 · Cited by 136 · see citing works

Inflammation in kidney repair: Mechanism and therapeutic potential

Fu, Y., Yu, X., Li, H., Chen, A., & Dong, Z. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108240 · Cited by 136 · see citing works

Clinical assessment of immune-related adverse events

Sosa, A. E., Cadena, E. L., Olivé, C. S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 135 · see citing works

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis

Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137 · see citing works

Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events

Davies, M. J., & Duffield, E. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 129 · see citing works

From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

Tocchetti, C. G., Dessalvi, C. C., Lisi, D. D., Femminò, S., Madonna, R., Mele, D., Monte, I. P., Novo, G., Penna, C. R. R., Pepe, A., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6930 · Cited by 126 · see citing works

Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area

Mir, H. R., Alhussein, M. M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S. D., Nair, V., & Leong, D. P. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.012 · Cited by 123 · see citing works

Cardiotoxicity from immune checkpoint inhibitors

Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 125 · see citing works

Immune Checkpoint Inhibitor Toxicity

Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 123 · see citing works

Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors

Ji, C., Roy, M. D., Golas, J., Vitsky, A., Ram, S., Kumpf, S. W., Martin, M. T., Barletta, F., Meier, W. A., Hooper, A. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4083 · Cited by 120 · see citing works

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy

Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119 · see citing works

Checkpoint Inhibitors

Heinzerling, L., Toni, E. D., Schett, G. A., Hundorfean, G., & Zimmer, L. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0119 · Cited by 118 · see citing works

IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein

Uversky, V. N., Redwan, E. M. M. M., Makis, W., & Rubio‐Casillas, A. (2023) · Vaccines · doi:10.3390/vaccines11050991 · Cited by 118 · see citing works

Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms

Champion, S. N., & Stone, J. R. (2019) · Modern Pathology · doi:10.1038/s41379-019-0363-0 · Cited by 115 · see citing works

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action

Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107 · see citing works

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 108 · see citing works

Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors

Laenens, D., Yu, Y., Santens, B., Jacobs, J., Beuselinck, B., Bechter, O. E., Wauters, E., Staessen, J. A., Janssens, S. P., & Aelst, L. N. L. V. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01808 · Cited by 108 · see citing works

Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity

Michel, L., Rassaf, T., & Totzeck, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.15 · Cited by 108 · see citing works

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data

Dudnik, E., Moskovitz, M. T., Daher, S., Shamai, S., Hanovich, E., Grubstein, A., Shochat, T., Wollner, M., Bar, J., Merimsky, O., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.015 · Cited by 103 · see citing works

Cardiorenal complications of immune checkpoint inhibitors

Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 106 · see citing works

Hematological immune related adverse events after treatment with immune checkpoint inhibitors

Kramer, R., Zaremba, A., Moreira, A., Ugurel, S., Johnson, D. B., Hassel, J. C., Salzmann, M., Gesierich, A., Weppler, A. M., Spain, L. A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.013 · Cited by 104 · see citing works

Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer

Chitturi, K. R., Xu, J., Araujo‐Gutierrez, R., Bhimaraj, A., Guha, A., Hussain, I., Kassi, M., Bernicker, E., & Trachtenberg, B. H. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.11.013 · Cited by 102 · see citing works

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management

Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 101 · see citing works

Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin

Jain, V., Mohebtash, M., Rodrigo, M. E., Ruiz, G., Atkins, M. B., & Barac, A. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000239 · Cited by 96 · see citing works

Cardiotoxicity of Anticancer Therapeutics

Dong, J., & Chen, H. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00009 · Cited by 95 · see citing works

Identifying and managing the adverse effects of immune checkpoint blockade

Winer, A., Bodor, J. N., & Borghaei, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.111 · Cited by 96 · see citing works

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology

Chen, D., Huang, W., Wu, V. C., Chang, W., Chen, J., Chuang, C., & Chu, P. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.07.025 · Cited by 96 · see citing works

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 97 · see citing works

Cardiac Complications in Immune Checkpoint Inhibition Therapy

Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 93 · see citing works

Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation

Bockstahler, M., Fischer, A., Goetzke, C. C., Neumaier, H. L., Sauter, M., Kespohl, M., Müller, A., Meckes, C., Salbach, C., Schenk, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043171 · Cited by 89 · see citing works

Cardiotoxicity of Immune Checkpoint Inhibitors

Zhang, L., Jones‐O’Connor, M., Awadalla, M., Zlotoff, D. A., Thavendiranathan, P., Groarke, J. D., Villani, A., Lyon, A. R., & Neilan, T. G. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0731-6 · Cited by 88 · see citing works

Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling

Xia, W., Zou, C., Chen, H., Xie, C., & Hou, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02778-2 · Cited by 88 · see citing works

T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword

Simons, K. H., de Jong, A., Jukema, J. W., de Vries, M. R., Arens, R., & Quax, P. H. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0164-7 · Cited by 88 · see citing works

Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases

Atallah‐Yunes, S. A., Kadado, A. J., Kaufman, G. P., & Hernández-Montfort, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02927-x · Cited by 88 · see citing works

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients

Sarocchi, M., Grossi, F., Arboscello, E., Bellodi, A., Genova, C., Bello, M. G. D., Rijavec, E., Barletta, G., Rossi, G., Biello, F., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0452 · Cited by 87 · see citing works

A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma

Ma, H., Chang, H., Yang, W., Lu, Y., Hu, J., & Jin, S. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1123-y · Cited by 87 · see citing works

Cardiovascular Complications Associated With Novel Cancer Immunotherapies

Jain, V., Bahia, J., Mohebtash, M., & Barac, A. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0532-8 · Cited by 86 · see citing works

Non-ischemic dilated cardiomyopathy and cardiac fibrosis

Cojan-Minzat, B. O., Zlibut, A., & Agoşton-Coldea, L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09940-0 · Cited by 83 · see citing works

Managing cardiotoxicity associated with immune checkpoint inhibitors

Upadhrasta, S., Elias, H., Patel, K., & Zheng, L. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.02.004 · Cited by 82 · see citing works

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature

Agrawal, N., Khunger, A., Vachhani, P. J., Colvin, T. A., Hattoum, A., Spangenthal, E. J., Curtis, A. B., Dy, G. K., Ernstoff, M. S., & Puzanov, I. J. (2019) · Case Reports in Oncology · doi:10.1159/000498985 · Cited by 80 · see citing works

Exploring immune checkpoints as potential therapeutic targets in atherosclerosis

Kusters, P. J. H., Lutgens, E., & Seijkens, T. T. P. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx248 · Cited by 80 · see citing works

Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure

Waliany, S., Lee, D. C., Witteles, R. M., Neal, J. W., Nguyen, P. K. P., Davis, M. M., Salem, J., Wu, S. M., Moslehi, J. J., & Zhu, H. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023451 · Cited by 75 · see citing works

Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer

Rocca, C., Soda, T., Francesco, E. D. D., Fiorillo, M., Moccia, F., Viglietto, G., Angelone, T., & Amodio, N. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04498-5 · Cited by 82 · see citing works

Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy

Tajmir-Riahi, A., Bergmann, T., Schmid, M., Agaimy, A., Schuler, G., & Heinzerling, L. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000190 · Cited by 78 · see citing works

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 77 · see citing works

PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor–related cardiac dysfunction

Xia, W., Chen, H., Chen, D., Ye, Y., Xie, C., & Hou, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001293 · Cited by 75 · see citing works

Supportive care for patients undergoing immunotherapy

Rapoport, B. L., Eeden, R. I. V., Sibaud, V., Epstein, J. B., Klastersky, J. A., Aapro, M., & Moodley, S. D. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3802-9 · Cited by 76 · see citing works

Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review

Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 74 · see citing works

Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment

Gergely, T. G., Kucsera, D., Tóth, V. É., Kovács, T., Sayour, N. V., Drobni, Z. D., Ruppert, M., Petrovich, B., Ágg, B., Onódi, Z., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15984 · Cited by 74 · see citing works

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab

Reuben, A., de Macêdo, M. P., McQuade, J. L., Joon, A. Y., Ren, Z., Calderone, T. L., Conner, B., Wani, K., Cooper, Z. A., Tawbi, H. A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1361097 · Cited by 72 · see citing works

Fatal Myocarditis Following Treatment with the PD ‐1 Inhibitor Nivolumab

Matson, D. R., Accola, M. A., Rehrauer, W. M., & Corliss, R. F. (2017) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13633 · Cited by 71 · see citing works

Immune checkpoint inhibitor-related myocarditis

Tajiri, K., Aonuma, K., & Sekine, I. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx154 · Cited by 71 · see citing works

Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Lemiale, V., Meert, A., Vincent, F., Darmon, M., Bauer, P. R., de Louw, A. V., & Azoulay, É. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0487-x · Cited by 70 · see citing works

A review of serious adverse effects under treatment with checkpoint inhibitors

Heinzerling, L., & Goldinger, S. M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000358 · Cited by 67 · see citing works

PD-1 checkpoint inhibition: Toxicities and management

Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.005 · Cited by 67 · see citing works

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

Pirozzi, F., Poto, R., Aran, L., Cuomo, A., Galdiero, M. R., Spadaro, G., Abete, P., Bonaduce, D., Marone, G., Tocchetti, C. G., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01002-w · Cited by 66 · see citing works

Melanoma and Immune Checkpoint Inhibitors

Furue, M., Ito, T., Wada, N. A., Wada, M., Kadono, T., & Uchi, H. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0676-z · Cited by 67 · see citing works

Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases

Zotova, L. (2023) · Diagnostics · doi:10.3390/diagnostics13071243 · Cited by 64 · see citing works

Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy

Sobol, I., Chen, C. L., Mahmood, S., & Borczuk, A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0447-oa · Cited by 64 · see citing works

Toxicity profiles of immunotherapy

Cousin, S., Sénéschal, J., & Italiano, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.005 · Cited by 63 · see citing works

Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy

de Almeida, D. V. P., Gomes, J. R., Haddad, F. J., & Buzaid, A. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000217 · Cited by 62 · see citing works

Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion

Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 69 · see citing works

Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review

Pradhan, R., Nautiyal, A., & Singh, S. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.025 · Cited by 62 · see citing works

An immunogenomic signature for molecular classification in hepatocellular carcinoma

Zhuang, W., Sun, H., Zhang, S., Zhou, Y., Weng, W., Wu, B., Ye, T., Huang, W., Lin, Z., Shi, L., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.024 · Cited by 61 · see citing works

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer

Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554313 · Cited by 63 · see citing works

Fibrosis and cancer: shared features and mechanisms suggest common targeted therapeutic approaches

Landolt, L. Z., Spagnoli, G. C., Hertig, A., Brochériou, I., & Marti, H. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa301 · Cited by 60 · see citing works

Cardiotoxicity of immune checkpoint inhibitors

Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247 · see citing works

Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue

Varricchi, G., Marone, G., Mercurio, V., Galdiero, M. R., Bonaduce, D., & Tocchetti, C. G. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170407125017 · Cited by 117 · see citing works

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 108 · see citing works

Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

Zhang, J.-C., Chen, W., Alvarez, J. B., Jia, K. Q., Shi, L., Wang, Q., Zou, N., He, K., & Hua Zhu, C. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0062-2 · Cited by 54 · see citing works

Cardiac Toxicities of Immune Checkpoint Inhibitors: MoreAwareness is Needed

Nicolas, J., & Nicolas, J. (2024) · Journal of Cardiology Research Review & Reports · doi:10.47363/jcrrr/2024(5)196